|
|
|
Insider
Information: |
Kamdar Kim P. |
Relationship: |
Director |
City: |
Princeton |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
184,574 |
|
Indirect Shares
|
3,947,811 |
|
|
Direct
Value |
$7,380,007 |
|
|
Indirect Value
|
$513,261 |
|
|
Total
Shares |
4,132,385 |
|
|
Total
Value |
$7,893,268 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Clovis Oncology, Inc. |
CLVS |
10% Owner |
|
0 |
2011-11-15 |
32,758 |
Premium* |
|
Orexigen Therapeutics, Inc. |
OREX |
10% Owner |
|
0 |
2011-01-01 |
1,963 |
Premium* |
|
Cadence Pharmaceuticals Inc |
CADX |
10% Owner |
|
0 |
2014-03-19 |
0 |
Premium* |
|
Achillion Pharmaceuticals Inc |
ACHN |
10% Owner |
|
0 |
2011-01-01 |
25,000 |
Premium* |
|
Zogenix, Inc. |
ZGNX |
10% Owner |
|
0 |
2011-01-01 |
11,000 |
Premium* |
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2014-11-17 |
0 |
2012-07-18 |
6,250 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
10% Owner |
|
0 |
2013-06-25 |
21,471 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2017-12-11 |
0 |
2013-07-15 |
47,963 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
10% Owner |
2016-11-01 |
0 |
2013-08-21 |
17,171 |
Premium* |
|
Evoke Pharma Inc |
EVOK |
10% Owner |
|
0 |
2013-09-24 |
5,250 |
Premium* |
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
2014-05-01 |
10,358 |
|
0 |
Premium* |
|
Marinus Pharmaceuticals Inc |
MRNS |
10% Owner |
2014-07-31 |
42,550 |
|
0 |
Premium* |
|
Evofem Biosciences Inc |
EVFM |
Director |
2023-12-21 |
0 |
2019-05-21 |
0 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
10% Owner |
2015-05-06 |
12,572 |
|
0 |
Premium* |
|
Glaukos Corp |
GKOS |
10% Owner |
2015-06-24 |
63,200 |
|
0 |
Premium* |
|
ReShape Lifesciences Inc |
RSLS |
Director |
2019-08-06 |
27,148 |
2016-10-12 |
0 |
Premium* |
|
Singular Genomics Systems, Inc. |
OMIC |
Director |
2023-08-15 |
15,000 |
2023-08-15 |
3,778,985 |
Premium* |
|
Sera Prognostics, Inc. |
SERA |
Director |
2024-06-06 |
13,746 |
2024-06-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ZGNX |
Zogenix, Inc. |
10% Owner |
|
2011-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
11,000 |
|
- |
|
TBRA |
Tobira Therapeutics Inc |
10% Owner |
|
2013-08-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
17,171 |
|
- |
|
TBRA |
Tobira Therapeutics Inc |
10% Owner |
|
2015-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
36,187 |
38,094 |
0 |
- |
|
TBRA |
Tobira Therapeutics Inc |
10% Owner |
|
2016-11-01 |
4 |
D |
$28.35 |
$1,079,965 |
D/D |
(38,094) |
0 |
0 |
- |
|
SERA |
Sera Prognostics, Inc. |
Director |
|
2024-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,117 |
13,746 |
0 |
- |
|
RSLS |
ReShape Lifesciences Inc |
Director |
|
2016-10-12 |
4 |
B |
$15.00 |
$201,000 |
D/D |
13,400 |
13,400 |
2.39 |
- |
|
RSLS |
ReShape Lifesciences Inc |
Director |
|
2018-08-23 |
4 |
B |
$1.82 |
$100,000 |
D/D |
54,945 |
68,345 |
2.39 |
- |
|
RSLS |
ReShape Lifesciences Inc |
Director |
|
2019-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
78,125 |
146,470 |
0 |
- |
|
RSLS |
ReShape Lifesciences Inc |
Director |
|
2019-08-06 |
4 |
B |
$4.00 |
$50,000 |
D/D |
12,500 |
27,148 |
2.39 |
- |
|
OREX |
Orexigen Therapeutics, In... |
10% Owner |
|
2011-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,963 |
|
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,000 |
|
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,000 |
|
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2021-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
4,395,633 |
4,495,633 |
0 |
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2023-08-11 |
4 |
S |
$0.60 |
$210,603 |
I/I |
(353,657) |
4,041,976 |
0 |
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2023-08-14 |
4 |
S |
$0.57 |
$44,424 |
I/I |
(77,991) |
3,963,985 |
0 |
- |
|
OMIC |
Singular Genomics Systems... |
Director |
|
2023-08-15 |
4 |
S |
$0.53 |
$106,960 |
I/I |
(200,000) |
3,763,985 |
0 |
- |
|
OCRX |
Ocera Therapeutics Inc |
10% Owner |
|
2013-07-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
47,963 |
|
- |
|
OCRX |
Ocera Therapeutics Inc |
10% Owner |
|
2017-12-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(47,963) |
0 |
0 |
- |
|
MRNS |
Marinus Pharmaceuticals I... |
10% Owner |
|
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,550 |
|
- |
|
LIFE |
aTyr Pharma Inc |
10% Owner |
|
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,572 |
|
- |
|
GKOS |
Glaukos Corp |
10% Owner |
|
2015-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
63,200 |
|
- |
|
EVOK |
Evoke Pharma Inc |
10% Owner |
|
2013-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,250 |
|
- |
|
EVFM |
Evofem Biosciences Inc |
Director |
|
2014-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,934 |
|
- |
|
EVFM |
Evofem Biosciences Inc |
Director |
|
2019-05-21 |
4 |
S |
$5.07 |
$3,321 |
I/I |
(655) |
0 |
0 |
- |
|
EVFM |
Evofem Biosciences Inc |
Director |
|
2019-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,287 |
4,287 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|